Le Lézard
Classified in: Health
Subjects: OFR, PVP

Aion Therapeutic Announces Closing of Non-Brokered Private Placement Offering of Units


TORONTO, Aug. 14, 2023 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated July 4, 2023, it has closed its previously-announced non-brokered private placement (the "Unit Offering") of 42,750,000 units ("Units") at a price of $0.01 per Unit for gross proceeds of $427,500.

Each Unit consists of one common share ("Share") and one half of one common share purchase warrant ("Warrant"). Each full Warrant is exercisable to acquire one Share ("Warrant Share") for a period of eighteen months following the closing of the Unit Offering at an exercise price of $0.10 per Warrant Share.

The Company intends to use the proceeds of the Unit Offering for general working capital purposes. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) except pursuant to an available exemption under the 1933 Act and compliance with, or exemption from, applicable U.S. state securities laws.

About Aion Therapeutic Inc.

Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.

DISCLAIMER & READER ADVISORY

This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward looking statements in this press release include statements regarding the use of proceeds from the Unit Offering. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information.

In addition, the forward- looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances.

The securities of the Company have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release is issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

SOURCE AION THERAPEUTIC INC.


These press releases may also interest you

at 04:22
Telix Pharmaceuticals Limited today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.[1] 2023 highlights Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022...

at 03:56
Dr. Paul Vitenas, a board-certified plastic surgeon based in Houston, Texas, has earned the prestigious title of Castle Connolly Top Doctor for the 20th consecutive year. This recognition demonstrates his dedication, expertise, and the exceptional...

at 03:43
Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data on dose linearity and systemic exposure from the first study...

at 03:30
Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is...

at 03:30
STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig,...

at 03:22
With its unprecedented precision, quantum sensing holds the potential to reform biomedical and health sciences by improving the diagnosis and prevention of diseases. The Novo Nordisk Foundation has awarded a grant of DKK 150 million to establish the...



News published on and distributed by: